207451-81-8

Usage

Uses

Used in Pharmaceutical Industry:
7-METHYL-1,2,3,4-TETRAHYDRO-ISOQUINOLINE is used as a precursor in the synthesis of pharmaceutical compounds for its potential biological activities and therapeutic applications.
Used in Neurotransmission Research:
7-METHYL-1,2,3,4-TETRAHYDRO-ISOQUINOLINE is used as a research compound in the study of neurotransmission due to its role as a neurotransmitter, which may contribute to understanding and developing treatments for neurological disorders.
Used in Analgesic Development:
7-METHYL-1,2,3,4-TETRAHYDRO-ISOQUINOLINE is used as a potential analgesic agent in the development of pain relief medications, leveraging its studied properties to alleviate pain effectively.
Used in Organic Synthesis:
7-METHYL-1,2,3,4-TETRAHYDRO-ISOQUINOLINE is used as a building block in organic synthesis for the creation of various organic molecules, taking advantage of its unique structure and reactivity.

InChI:InChI=1/C10H13N/c1-8-2-3-9-4-5-11-7-10(9)6-8/h2-3,6,11H,4-5,7H2,1H3

Upstream product

• 371756-25-1 7-methyl-1,2,3,4-tetrahydroisoquinolin-1-one 
• 859075-93-7 N-benzenesulfonyl-N-(4-methyl-phenethyl)-glycine 
• 104-87-0 4-methyl-benzaldehyde 
• 3261-62-9 2-(p-tolyl)ethylamine 
• 26011-73-4 N-[2-(p-tolyl)ethyl] acetamide 
• 101671-00-5 (Z)-1-methyl-4-(2-nitrovinyl)benzene 
• 207451-83-0 1-(7-Methyl-3,4-dihydro-1H-isoquinolin-2-yl)-ethanone 
• 859191-64-3 2-benzenesulfonyl-7-methyl-1,2,3,4-tetrahydro-isoquinoline 

Downstream Products

• 1430216-32-2 C₂₉H₂₅ClN₆O₄ 
• 508237-09-0 5-(3,4-Dimethoxybenzylamino)-2-(2-furyl)-8-(7-methyl-1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)[1,2,4]triazolo[1,5-c]pyrimidine 
• 207451-83-0 1-(7-Methyl-3,4-dihydro-1H-isoquinolin-2-yl)-ethanone 

Relevant academic research and scientific papers

Catalyst-free cyclization of anthranils and cyclic amines: One-step synthesis of rutaecarpine

An efficient synthesis of a variety of quinazolinone derivatives via a direct cyclization reaction between commercially available anthranils and cyclic amines is described. The developed transformation proceeds with the merits of high step- and atom-efficiency, a broad substrate scope, and good to excellent yields, without additional catalysts, and offers a practical way for the preparation of rutaecarpine and its derivatives with structural diversity.

The influence of substitution at aromatic part of 1,2,3,4-tetrahydroisoquinoline on in vitro and in vivo 5-HT1A/5-HT2A receptor activities of its 1-adamantoyloaminoalkyl derivatives

Further structure-activity relationship (SAR) studies with the 1,2,3,4-tetrahydroisoquinoline (THIQ) class of 5-HT1A ligands led to the synthesis of new 1-adamantoyloaminoalkyl derivatives. The impact of substituent variations in the aromatic part of THIQ moiety on 5-HT1A and 5-HT2A receptor affinities, as well as in vivo functional properties of the investigated compounds were discussed. It was found that modification reduced the binding affinity for 5-HT1A receptors (in comparison with unsubstituted THIQ derivatives); however, the majority of new compounds still remained potent 5-HT1A ligands (Ki = 4.9-46 nM) and most of them showed features of partial agonists of postsynaptic 5-HT1A receptors. At the same time, their 5-HT2A receptor affinity was slightly increased (Ki = 40-1475 nM), which resulted in a loss of 5-HT2A/5-HT1A selectivity. 5-Br,8-OCH3 derivative - the most potent, mixed 5-HT1A/5-HT2A ligand - produced activation of presynaptic 5-HT1A receptors and showed properties of a 5-HT2A receptor antagonist. Copyright